We performed a study to assess the efficacy of fenoldopam mesylate (a specific agonist of the dopamine-1 receptor) as compared with N-acetylcysteine (NAC) in preventing contrast agent-associated nephrotoxicity (CAN). BACKGROUND Prophylactic administration of NAC, along with hydration, prevents CAN in patients with chronic renal insufficiency who are undergoing contrast media administration. Preliminary data support the hypothesis that fenoldopam might be as effective as NAC.
Radiocontrast media can lead to a reversible form of acute renal failure that, especially in high-risk patients, may require transient dialysis and may impair in-hospital and long-term outcomes (1-3). The two major mechanisms of contrastassociated nephrotoxicity (CAN) are renal vasoconstriction (4) and direct toxic effects of the contrast agents (5, 6) . Recommendations to prevent CAN are: 1) periprocedural hydration (7) , 2) the use of a low-or iso-osmolality contrast (8 -11) , and 3) limiting the amount of contrast agent (12) . Recently, two additional strategies associated with to hydration aroused considerable interest: N-acetylcysteine (NAC) and fenoldopam mesylate; the former, a potent antioxidant compound, may prevent the direct oxidative tissue damage by scavenging reactive oxygen species (13) , whereas the latter, a specific dopamine-1 receptor agonist that causes peripheral vasodilatation via stimulation of postsynaptic dopamine-1 receptors (14) , may prevent renal vasoconstriction (15) (16) (17) (18) .
We performed a prospective, randomized trial comparing the safety and prophylactic effectiveness of NAC plus hydration versus fenoldopam mesylate plus hydration in patients with chronic renal insufficiency undergoing coronary or peripheral artery procedures.
METHODS
Patient population. This is a prospective, randomized study conducted in our institutions from March to December 2003. The local ethics committee ("Vita e Salute" University School of Medicine, Milan, Italy) approved the study protocol. All patients gave written informed consent. Consecutive patients scheduled for elective coronary and/or peripheral angiography and/or angioplasty were eligible for the study if they had chronic impairment of renal function (serum creatinine concentration Ն1.5 mg/dl and/or creatinine clearance Ͻ60 ml/ min) and stable serum creatinine concentrations. Patients were randomly assigned to receive intravenous saline plus NAC (NAC group) or fenoldopam mesylate (fenoldopam group) before and after administration of iodixanol (Visipaque, 320 mg iodine/ml, Amersham Health, Amersham, United Kingdom) a non-ionic, iso-osmolality contrast agent. Saline (0.45%) was given intravenously at a rate of 1 ml/kg of body weight/h (0.5 ml/kg for patients with left ventricular ejection fraction [LVEF] Ͻ40%) for 12 h before and 12 h after administration of the contrast agent (7) . N-acetylcysteine (Fluimucil, Zambon Group Spa, Milan, Italy) was given orally at a dose of 1,200 mg twice daily in the NAC group on the day before and on the day of administration of the contrast agent for a total of two days (19) . Fenoldopam mesylate (Corlopam, Elan Pharma Italia, Rome, Italy) infusion was started at least 1 h before the procedure at 0.10 g/kg/min, maintained during the procedure, and continued for 12 h after the procedure. The dosage was downtitrated or discontinued in cases of hypotension or tachycardia (20) . Severe hypotension was defined as a systolic blood pressure Ͻ90 mm Hg. None of the patients received theophylline, dopamine, mannitol, or furosemide during the study. Serum creatinine, blood urea nitrogen, sodium, and potassium were measured immediately before and 48 h after administration of the contrast agent; additional measurements were performed in all cases of significant impairment of renal function. Creatinine clearance was calculated by applying the Cockcroft-Gault formula (21) . Study end point. Contrast agent-associated nephrotoxicity was defined as an increase in the serum creatinine concentration Ն0.5 mg/dl of the baseline value 48 h or need for dialysis after administration of the contrast media (8) . Acute renal failure requiring dialysis was defined as a decrease in renal function necessitating acute hemodialysis, ultrafiltration, or peritoneal dialysis in the first five days postintervention.
Statistical analysis.
A total sample size of 180 subjects randomized with a 1:1 allocation ratio was calculated to achieve a power (1 Ϫ ␤) of 90% to detect a difference of 10% between the null hypothesis that both group proportions are 5% and the alternative hypothesis that the proportion in the NAC group is 5% (19) and in the fenoldopam group is 15% (17,20) using a two-sided chi-square test with a significance level of 0.05. Continuous variables are given as mean Ϯ 1 SD or median and interquartile ranges. An unpaired Student t test was performed to determine differences between mean values for continuous variables when appropriate. Categorical variables were analyzed by using the chi-square test. Creatinine concentration was not normally distributed; therefore, the nonparametric Wilcoxon rank-sum test and Mann-Whitney U test were used to assess differences. Probability values Ͻ0.05 were considered significant. Data were analyzed with SPSS 10.0 (SPSS Inc., Chicago, Illinois) for Windows. Tables 1 and 2 . Three patients experienced side effects in the fenoldopam group that necessitated premature drug infusion discontinuation: two patients had severe hypoten- Renal failure requiring dialysis occurred in one patient enrolled in the fenoldopam group (1.1%): this patient subsequently experienced in-hospital death. Length of inhospital stay (from admission to discharge) was longer in the fenoldopam group than NAC group (5.0 Ϯ 10 days vs. 2.9 Ϯ 2.7 days; p ϭ 0.049).
RESULTS

Clinical characteristics. The clinical and biochemical characteristics of the 192 enrolled patients are shown in
DISCUSSION
Contrast agent-associated nephrotoxicity represents the third cause of in-hospital renal function deterioration after decreased renal perfusion and postoperative renal insufficiency (22) . An optimal strategy to prevent CAN remains unknown. Recently, two additional strategies associated with hydration aroused considerable interest: NAC and fenoldopam mesylate. NAC and CAN. The quite low incidence of CAN in the NAC group (4.1%) observed in the present study confirms what we previously reported (19) . A potent antioxidant that scavenges a wide variety of oxygen-derived free-radicals, NAC may prevent CAN by avoiding direct oxidative tissue damage and also by improving renal hemodynamics (23) (24) (25) . Tepel et al. (13) first reported that NAC plus hydration is more effective than hydration alone in preventing CAN. A recent meta-analysis evaluating more than 800 high-risk patients enrolled in randomized controlled trials supports that NAC plus hydration significantly reduces the risk of CAN in patients with chronic renal insufficiency (26) . We used a dosing regimen that was double (1,200 mg orally twice daily) (19) that suggested by Tepel et al. (13) because the antioxidant effect of NAC seems to be dose-dependent (27) . With large volumes of contrast dye, the beneficial effect of the NAC may be evident only by using a dosing regimen double that suggested by Tepel et al. (13) .
Fenoldopam and CAN.
Fenoldopam mesylate is the first selective dopamine-1 receptor agonist approved for the in-hospital treatment of patients with severe hypertension (14) . A low dosage of fenoldopam that does not decrease systemic blood pressure produces dopamine-1 receptormediated dose-related renal vasodilatation, diuresis, and natriuresis (14) . In dogs, fenoldopam protects against the acute renal vasoconstriction that may be induced by contrast agents (16 (20) , which suggested that fenoldopam mesylate is ineffective in preventing further renal function deterioration in patients with chronic renal insufficiency receiving iodinated contrast. According to these findings and considering also the high cost of this drug, a strategy of hydration plus fenoldopam mesylate should not be used as a prophylactic measure to prevent CAN. Study limitations. Our study was not blinded. Fenoldopam mesylate increases renal blood flow in a dose-dependent manner (14) ; hence, a dose Ͼ0.10 g/kg/min may be needed to achieve an optimal prophylactic action against CAN. Increasing the dose, however, increases the risk of hypotension with resultant intrarenal vasoconstriction.
Reprint requests and correspondence: Dr. Carlo Briguori, Interventional Cardiology, Clinica Mediterranea, Via Orazio, 2, I-80121, Naples, Italy. E-mail: briguori.carlo@hsr.it.
